NR3C2 and chronic kidney disease: In particular, finerenone, a non-steroidal selective mineralocorticoid receptor antagonist, has recently been shown to reduce the risk of CKD progression in adults with T2D in the Efficacy and Safety of Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD) study (143).